AdAlta Limited (ASX:1AD)
Australia · Delayed Price · Currency is AUD 0.0030
0.00 (0.00%)
Sep 18, 2026, 3:08 PM AEST
AdAlta Market Cap
AdAlta has a market cap or net worth of 9.64 million as of September 17, 2026. Its market cap has increased by 88.55% in one year.
Market Cap
9.64M
Enterprise Value
8.35M
Revenue
404.25K
Ranking
n/a
PE Ratio
n/a
Stock Price
0.00
ChartMarket Cap Chart
Since August 22, 2016, AdAlta's market cap has decreased from 28.00M to 9.64M, a decrease of -65.58%. That is a compound annual growth rate of -10.04%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 18, 2026 | 9.64M | 39.95% |
| Dec 31, 2025 | 6.89M | -31.84% |
| Dec 30, 2024 | 10.10M | -19.94% |
| Dec 29, 2023 | 12.62M | -2.04% |
| Dec 29, 2022 | 12.88M | -45.79% |
| Dec 29, 2021 | 23.76M | -22.47% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Neurotech International | 17.20M |
| Immuron | 14.21M |
| Ceryvyn Therapeutics | 13.68M |
| Cambium Bio | 13.54M |
| ReNerve | 12.23M |
| Invex Therapeutics | 8.64M |
| Bio-Gene Technology | 7.45M |
| Vectus Biosystems | 7.40M |